Immuneering Corp
IMRX3.350USD
-0.020-0.59%
交易中 （美东）报价延迟15分钟
120.55M总市值
亏损市盈率 TTM
关于 Immuneering Corp 公司
Immuneering Corporation 是一家临床阶段的肿瘤学公司。该公司致力于开发具有通用 RAS 疗法的癌症患者药物。该公司的主要候选产品 IMM-1-104 正在针对携带 RAS 突变的晚期实体瘤患者进行 I/IIa 期临床试验。IMM-1-104 正在开发为每日一次的口服单一疗法，旨在通过深度周期性抑制 MAPK 通路实现通用 RAS 活性。该公司的第二个候选产品 IMM-6-415 旨在通过加速每日两次口服给药节奏实现通用 MAPK 活性，同样是通过深度周期性抑制 MAPK 通路实现的。IMM-6-415 正在申请新药临床试验 (IND)，支持开展研究。其产品线还包括 Trifecta MEK、RAS 调节剂和其他小分子药物发现计划。该公司的平台由两个关键元素支持：生物信息学和 3D 肿瘤建模。
公司简介
公司代码IMRX
公司名称Immuneering Corp
上市日期Jul 30, 2021
CEODr. Benjamin J. (Ben) Zeskind, Ph.D.
员工数量66
证券类型Ordinary Share
年结日Jul 30
公司地址245 Main Street, Second Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02142
电话16175008080
网址https://immuneering.com/
公司代码IMRX
上市日期Jul 30, 2021
CEODr. Benjamin J. (Ben) Zeskind, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Director
Independent Director
14.00K
--
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
12.74K
+53.85%
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
10.73K
+6.98%
Dr. Igor Matushansky, M.D., Ph.D.
Dr. Igor Matushansky, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Diana F. Hausman, M.D.
Dr. Diana F. Hausman, M.D.
Independent Director
Independent Director
--
--
Mr. Michael D. Bookman
Mr. Michael D. Bookman
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Director
Independent Director
14.00K
--
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
12.74K
+53.85%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Zeskind (Benjamin J)
8.91%
Merrin Investors, L.L.C.
7.70%
Carpenter (Robert J)
3.19%
Feinberg (Peter)
3.12%
The Vanguard Group, Inc.
2.94%
Other
74.14%
持股股东
持股股东
占比
Zeskind (Benjamin J)
8.91%
Merrin Investors, L.L.C.
7.70%
Carpenter (Robert J)
3.19%
Feinberg (Peter)
3.12%
The Vanguard Group, Inc.
2.94%
Other
74.14%
股东类型
持股股东
占比
Individual Investor
16.69%
Investment Advisor
8.05%
Corporation
7.70%
Investment Advisor/Hedge Fund
3.29%
Hedge Fund
0.89%
Research Firm
0.19%
Other
63.19%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
159
13.23M
36.78%
-6.28M
2025Q1
161
13.19M
41.31%
-6.04M
2024Q4
164
13.00M
41.85%
-6.73M
2024Q3
162
13.05M
42.83%
-8.70M
2024Q2
161
18.30M
60.87%
-2.07M
2024Q1
151
20.58M
69.02%
-6.37M
2023Q4
145
24.26M
82.88%
-4.62M
2023Q3
147
25.15M
85.99%
-3.63M
2023Q2
142
25.50M
87.18%
+568.32K
2023Q1
129
20.04M
76.48%
+592.90K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Zeskind (Benjamin J)
3.20M
8.89%
+21.00K
+0.66%
Jun 18, 2025
Merrin Investors, L.L.C.
2.77M
7.7%
--
--
Apr 17, 2025
Carpenter (Robert J)
1.15M
3.19%
--
--
Apr 17, 2025
Feinberg (Peter)
1.12M
3.12%
+25.00K
+2.28%
Jun 18, 2025
The Vanguard Group, Inc.
1.06M
2.94%
--
--
Mar 31, 2025
Marshall Wace LLP
807.97K
2.25%
+786.54K
+3669.92%
Mar 31, 2025
T. Rowe Price Associates, Inc.
659.01K
1.83%
-108.11K
-14.09%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
450.83K
1.25%
+15.09K
+3.46%
Mar 31, 2025
Hall (Brett Matthew)
359.32K
1%
+13.42K
+3.88%
Jun 23, 2025
BlackRock Institutional Trust Company, N.A.
311.91K
0.87%
-1.03K
-0.33%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Avantis US Small Cap Equity ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
Proshares Ultra Russell 2000
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Global X Russell 2000 ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
iShares Russell 2000 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Avantis US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
